Funding for this research was provided by:
Received: 3 June 2020
Accepted: 20 August 2020
First Online: 4 September 2020
Compliance with ethical standards
: J.L. Ebenau reports no conflict of interest. Dr. Sander C.J. Verfaillie reports no conflict of interest. Karlijn A. van den Bosch reports no conflict of interest. Tessa Timmers reports no conflict of interest. Dr. Linda M.P. Wesselman reports no conflict of interest. Mardou van Leeuwenstijn reports no conflict of interest. Hayel Tuncel reports no conflict of interest. Dr. Sandeep V.S. Golla reports no conflict of interest. Dr. Maqsood M. Yaqub reports no conflict of interest. Dr. Albert D. Windhorst reports no conflict of interest. Dr. Niels D. Prins reports consulting, advisory and speaker fees from Boehringer Ingelheim, Envivo, Janssen, Novartis, Probiodrug, Sanofi, Takeda, Kyowa Kirin Pharmaceutical Development, DSMB of AbbVie’s M15-566, grants from Alzheimer Nederland (all paid directly to his institution) outside the submitted work. Dr. Prins is CEO and co-owner of the Brain Research Centre, Amsterdam, The Netherlands. Dr. Frederik Barkhof is a consultant for Biogen-Idec, Janssen Alzheimer Immunotherapy, Bayer-Schering, Merck-Serono, Roche, Novartis, Genzume and Sanofi-Aventis; has received sponsoring from European Commission-Horizon 2020, National Institute for Health Research-University College London Hospitals Biomedical Research Centre, Scottish Multiple Sclerosis Register, TEVA, Novartis and Toshiba; and serves on the editorial boards of <i>Radiology</i>, <i>Brain</i>, <i>Neuroradiology</i>, <i>Multiple Sclerosis Journal</i>, and <i>Neurology.</i> Dr. Philip Scheltens has acquired grant support (for the institution) from Biogen. In the past 2 years, he has received consultancy/speaker fees (paid to the institution) from Probiodrug Biogen, EIP Pharma, Merck AG. Dr. Wiesje M. van der Flier’s research programs have been funded by ZonMW, the Netherlands Organization of Scientific Research, Alzheimer Nederland, Cardiovascular Onderzoek Nederland, Stichting Dioraphte, Gieskes-Strijbis fonds, Pasman stichting, Boehringer Ingelheim, Life-MI, AVID, Biogen MA and Combinostics. All funding is paid to her institution. Dr. Bart van Berckel has received funding from ZonMW, the Netherlands Organization of Scientific Research, the Centre of Translational Molecular Imaging and Avid Radiopharmaceuticals. All funding is paid to his institution.
: The research was approved by the Medical Ethics Review Committee of Amsterdam UMC. This study was performed in line with the principles of the Declaration of Helsinki.
: Written informed consent was obtained from all patients included in the study.